A post hoc analysis of the 5-year data from the GO-REVEAL trial showed that golimumab-treated patients with psoriatic arthritis (PsA) who achieved minimal disease activity (MDA) have better long-term outcomes than those who did not. GO-REVEAL was a phase III, randomized, double-blind, placebo-controlled trial in which patients with PsA were randomly assigned to receive placebo or golimumab (50 or 100 mg) subcutaneously every 4 weeks for 24 weeks, followed by an open-label extension to 5 years. At 5 years, ∼50% of golimumab-treated patients achieved MDA at least once. This post hoc analysis compares the outcomes of patients who did and did not achieve MDA, regardless of the treatment they received. Patients who achieved MDA at ≥3 consecutive visits showed improved radiographic outcomes, better long-term functional improvement and improved patient global assessments compared to patients who did not regularly achieve MDA.